Sophiris says it’s ready to get back on track with lead drug after patient death — but questions linger

Sophiris says it’s ready to get back on track with lead drug after patient death — but questions linger

Source: 
Endpoints
snippet: 

Sophiris’ shares $SPHS took a beating two months ago when the biotech disclosed that a patient died on the same day of a second administration of their drug topsalysin in a Phase IIb prostate cancer trial.